{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:12:34Z","timestamp":1787508754306,"version":"build-2736575974"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Theratechnologies"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Excess visceral abdominal fat (EVAF) is a prevalent metabolic complication among people living with HIV-1 (PLWH), occurring even in individuals with normal or mildly elevated body mass index (BMI). This pattern of fat accumulation is associated with metabolic dysfunction, cardiovascular risk, and reduced quality of life. Since EVAF can present without generalized obesity, weight-based assessments may fail to identify it; moreover, addressing EVAF warrants distinct approaches based on a patient's presentation. Two therapeutic classes have been studied in this setting: growth hormone\u2013releasing hormone analog (tesamorelin), which selectively reduces visceral fat, and glucagon-like peptide (GLP-1) receptor agonists, which induces generalized weight loss in a nonspecific way.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case Presentations<\/jats:title>\n                    <jats:p>Two adults with well-controlled HIV presented with central adiposity. The first patient demonstrated a nonobese visceral adiposity phenotype characterized by increased waist circumference (WC) and a BMI of 27 kg\/m\u00b2. Treatment with tesamorelin led to marked reductions in WC, improved lipid levels, and enhanced functional well-being. The second patient, a woman with higher BMI representative of obesity, received a GLP-1; however, her intermittent access to the medication resulted in fluctuating weight trends and persistent abdominal fat. Incorporation of tesamorelin provided a more targeted approach to reduce visceral adiposity in this context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both cases demonstrated that EVAF may persist independent of BMI category and may respond differently to therapies targeting generalized obesity versus selective visceral abdominal fat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These cases highlight the heterogeneity of EVAF in PLWH and support individualized management strategies informed by fat distribution rather than weight alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag121","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:36:14Z","timestamp":1772195774000},"page":"S87-S91","source":"Crossref","is-referenced-by-count":2,"title":["Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1476-1842","authenticated-orcid":false,"given":"Robin","family":"Beach","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine McGovern Medical School, The University of Texas Health Science Center, Houston , Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9104-6843","authenticated-orcid":false,"given":"Zandraetta","family":"Tims-Cook","sequence":"additional","affiliation":[{"name":"Faebris , Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen S","family":"McGary","sequence":"additional","affiliation":[{"name":"Theratechnologies Inc , Medical Affairs, Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanushree","family":"Thote","sequence":"additional","affiliation":[{"name":"Theratechnologies Inc , Medical Affairs, Montreal, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026051511400273600_ciag121-B1","first-page":"2358","article-title":"Body composition and metabolic changes in HIV infection and disease","volume":"373","author":"Stanley","year":"2015","journal-title":"N Engl J Med"},{"key":"2026051511400273600_ciag121-B2","doi-asserted-by":"crossref","first-page":"e54919","DOI":"10.1371\/journal.pone.0054919","article-title":"Visceral adiposity in HIV-infected and uninfected adults: associations with body mass index and waist circumference","volume":"8","author":"Lanyon","year":"2013","journal-title":"PLoS One"},{"key":"2026051511400273600_ciag121-B3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/cid\/ciae543","article-title":"Morbidity and mortality risk among people with HIV and central or visceral adiposity: a targeted literature review","volume":"80","author":"Bjornson","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2026051511400273600_ciag121-B4","first-page":"669","article-title":"The distinction between obesity and visceral adiposity in metabolic health","volume":"16","author":"Bl\u00fcher","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026051511400273600_ciag121-B5","doi-asserted-by":"crossref","first-page":"e0245436","DOI":"10.1371\/journal.pone.0245436","article-title":"Comparison of obesity and metabolic syndrome prevalence using fat mass index, body mass index and percentage body fat","volume":"16","author":"Wong","year":"2021","journal-title":"PLoS One"},{"key":"2026051511400273600_ciag121-B6","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/0002-9149(94)90676-9","article-title":"Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk","volume":"73","author":"Pouliot","year":"1994","journal-title":"Am J Cardiol"},{"key":"2026051511400273600_ciag121-B7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1093\/ajcn\/64.5.685","article-title":"A single threshold value of waist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue","volume":"64","author":"Lemieux","year":"1996","journal-title":"Am J Clin Nutr"},{"key":"2026051511400273600_ciag121-B8","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad398","article-title":"Visceral Adiposity Index as a Measure of Cardiovascular Disease in Persons With Human Immunodeficiency Virus","volume-title":"Open Forum Infectious Diseases","author":"Thomas","year":"2023"},{"key":"2026051511400273600_ciag121-B9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1079\/NRR19930010","article-title":"Effects of diet and physical activity on adiposity and body fat distribution: implications for the prevention of cardiovascular disease","volume":"6","author":"Despr\u00e9s","year":"1993","journal-title":"Nutr Res Rev"},{"key":"2026051511400273600_ciag121-B10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/oby.22742","article-title":"Measures of adipose tissue redistribution and atherosclerotic coronary plaque in HIV","volume":"28","author":"Bogorodskaya","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"2026051511400273600_ciag121-B11","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hep4.1695","article-title":"Hepatic steatosis and ectopic fat are associated with differences in subcutaneous adipose tissue gene expression in people with HIV","volume":"5","author":"Gabriel","year":"2021","journal-title":"Hepatol Commun"},{"key":"2026051511400273600_ciag121-B12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1093\/cid\/ciaa382","article-title":"Clinical predictors of liver fibrosis presence and progression in human immunodeficiency virus\u2013associated nonalcoholic fatty liver disease","volume":"72","author":"Fourman","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026051511400273600_ciag121-B13","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/QAD.0b013e32834884e6","article-title":"Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection","volume":"25","author":"Scherzer","year":"2011","journal-title":"AIDS"},{"key":"2026051511400273600_ciag121-B14","doi-asserted-by":"crossref","first-page":"1576599","DOI":"10.3389\/fendo.2025.1576599","article-title":"Visceral adiposity loss is associated with improvement in cardiometabolic markers: findings from a dietary intervention study","volume":"12","author":"Abdullah","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026051511400273600_ciag121-B15","author":"Mounzer"},{"key":"2026051511400273600_ciag121-B16","doi-asserted-by":"crossref","first-page":"e0194653","DOI":"10.1371\/journal.pone.0194653","article-title":"Markers of adiposity in HIV\/AIDS patients: agreement between waist circumference, waist-to-hip ratio, waist-to-height ratio and body mass index","volume":"13","author":"Dimala","year":"2018","journal-title":"PLoS One"},{"key":"2026051511400273600_ciag121-B17","volume-title":"Waist circumference and Waist\u2013hip ratio: report of a WHO expert consultation","author":"World Health Organization","year":"2011"},{"key":"2026051511400273600_ciag121-B18","doi-asserted-by":"crossref","first-page":"1411678","DOI":"10.3389\/fendo.2024.1411678","article-title":"Prediction of visceral adipose tissue magnitude using a new model based on simple clinical measurements","volume":"15","author":"Torun","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026051511400273600_ciag121-B19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a consensus statement from the IAS and ICCR working group on visceral obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"2026051511400273600_ciag121-B20","first-page":"305","article-title":"The role of growth hormone and the GH\u2013IGF-1 axis in HIV-related lipodystrophy","volume":"78","author":"Guaraldi","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026051511400273600_ciag121-B21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0002-9343(89)90225-8","article-title":"Hypertriglyceridemia in the acquired immunodeficiency syndrome","volume":"86","author":"Grunfeld","year":"1989","journal-title":"Am J Med"},{"key":"2026051511400273600_ciag121-B22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/hiv.12085","article-title":"Long-term safety and effects of tesamorelin, a growth hormone\u2013releasing factor analogue, in HIV-infected patients with abdominal fat accumulation","volume":"15","author":"Falutz","year":"2014","journal-title":"HIV Med"},{"key":"2026051511400273600_ciag121-B23","first-page":"178","article-title":"Metabolic effects of tesamorelin, a growth hormone\u2013releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized controlled trial","volume":"304","author":"Falutz","year":"2010","journal-title":"JAMA"},{"key":"2026051511400273600_ciag121-B24","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","article-title":"Effects of tesamorelin (TH9507), a growth hormone\u2013releasing factor analog, in HIV-infected patients with excess abdominal fat: pooled analysis of two multicenter, double-blind, placebo-controlled phase 3 trials with safety extension data","volume":"95","author":"Falutz","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051511400273600_ciag121-B25","author":"Theratechnologies Inc","year":"2025"},{"key":"2026051511400273600_ciag121-B26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026051511400273600_ciag121-B27","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/cid\/cix178","article-title":"Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection","volume":"64","author":"Lake","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_4\/S87\/68293160\/ciag121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/Supplement_4\/S87\/68293160\/ciag121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:40:09Z","timestamp":1778859609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/Supplement_4\/S87\/8678930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":27,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2026,5,15]]},"published-print":{"date-parts":[[2026,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag121","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,15]]},"published":{"date-parts":[[2026,5,15]]}}}